ANTI-PD-1 ZIMBERELIMAB

A monoclonal antibody that binds PD-1, restoring the antitumor activity of T cells

Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including several registrational Phase 3 studies in first-line metastatic, non-small cell lung cancer and upper gastrointestinal cancers.

Zimberelimab is currently approved in China for the treatment of classic Hodgkin Lymphoma (cHL). Gloria Biosciences secured the Chinese approval and holds commercial rights in China. It conducts its development activities independently of Arcus.